axicabtagene ciloleucel,cyclophosphamide,fludarabine
gilead
['zuma-7']
my #asco23 thread on zuma-7 os re-upped for #17icml impressive to show os benefit despite ~80% crossover* shows that a transformative therapy can both demonstrate os benefit &amp; do so with crossover *should have been built into study 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem